The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer.
Abstract
PURPOSE: To evaluate HER-2/neu-specific antibody immunity in patients with breast cancer, to determine the rate of occurrence of serum antibodies to HER-2/neu in patients with breast cancer, and to relate the presence of specific immunity to overexpression of HER-2/neu protein in primary tumor. METHODS: The antibody response to HER-2/neu protein was analyzed in 107 newly diagnosed breast cancer patients. Sera was analyzed for the presence of HER-2/neu-specific antibodies with a capture enzyme-linked immunosorbent assay (ELISA) and verified by Western blot. Sera from 200 volunteer blood donors was used as a control population. RESULTS: The presence of antibodies to HER-2/neu correlated with the presence of breast cancer. HER-2/neu antibodies at titers of > or = 1:100 were detected in 12 of 107 (11%) breast cancer patients versus none of 200 (0%) normal controls (P < .01). The presence of antibodies to HER-2/neu also correlated to overexpression of HER-2/neu protein in the patient's primary tumor. Nine of 44 (20%) patients with HER-2/neu-positive tumors had HER-2/neu-specific antibodies, whereas three of 63 (5%) patients with HER-2/neu-negative tumors had antibodies (P = .03). The antibody responses could be substantial. Titers of greater than 1:5,000 were detected in five of 107 (5%). CONCLUSION: The presence of HER-2/neu antibodies in breast cancer patients and the correlation with HER-2/neu-positive cancer implies that immunity to HER-2/neu develops as a result of exposure of patients to HER-2/neu protein expressed by their own cancer. These findings should stimulate further studies to develop the detection of immunity to oncogenic proteins as tumor markers, as well as the development and testing of vaccine strategies to induce and augment immunity to HER-2/neu for the treatment of breast cancer or prevention of recurrent disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Baselga, J., Tripathy, D., Mendelsohn, J., Baughman, S., Benz, C. C., Dantis, L., Sklarin, N. T., Seidman, A. D., Hudis, C. A., Moore, J., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.3.737 · Cited by 1,380
Gusterson, B. A., Gelber, R. D., Goldhirsch, A., Price, K. N., Säve-Söderborgh, J., Anbazhagan, R., Styles, J., Rudenstam, C. M., Golouh, R., & Reed, R. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.7.1049 · Cited by 838
Fisk, B., Blevins, T. L., Wharton, J. T., & Ioannides, C. G. (1995) · The Journal of experimental medicine · doi:10.1084/jem.181.6.2109 · Cited by 543
Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer.
Disis, M. L., Calenoff, E., McLaughlin, G., Murphy, A. E., Chen, W., Groner, B., Jeschke, M., Lydon, N., McGlynn, E., & Livingston, R. B. (1994) · PubMed · Cited by 524
Self-citationPeoples, G. E., Goedegebuure, P. S., Smith, R., Linehan, D. C., Yoshino, I., & Eberlein, T. J. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.2.432 · Cited by 439
Rilke, F., Colnaghi, M. I., Cascinelli, N., Andreola, S., Baldini, M. T., Bufalino, R., Porta, G. D., Ménard, S., Pierotti, M. A., & Testori, A. (1991) · International Journal of Cancer · doi:10.1002/ijc.2910490109 · Cited by 259
Oncogenic proteins as tumor antigens
Disis, M. L. (1996) · Current Opinion in Immunology · doi:10.1016/s0952-7915(96)80079-3 · Cited by 154
Self-citationBacus, S. S., Stancovski, I., Huberman, E., Chin, D., Hurwitz, E., Mills, G. B., Ullrich, A., Sela, M., & Yarden, Y. (1992) · PubMed · Cited by 101
Cited by
Cancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893
Ross, J. S., Slodkowska, E. A., Symmans, W. F., Pusztai, L., Ravdin, P. M., & Hortobagyi, G. N. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0230 · Cited by 1,144
DeNardo, D. G., & Coussens, L. M. (2007) · Breast Cancer Research · doi:10.1186/bcr1746 · Cited by 677
The HER-2/neu Gene and Protein in Breast Cancer 2003: Biomarker and Target of Therapy
Ross, J. S., Fletcher, J. A., Linette, G. P., Stec, J., Clark, E., Ayers, M., Symmans, W. F., Pusztai, L., & Bloom, K. J. (2003) · The Oncologist · doi:10.1634/theoncologist.8-4-307 · Cited by 610
Biochemical and Clinical Implications of the ErbB/HER Signaling Network of Growth Factor Receptors
(1999) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60784-8 · Cited by 540
Metadata
- Authors
- Disis, M. L., Pupa, S. M., Gralow, J. R., Dittadi, R., Menard, S., & Cheever, M. A.
- Venue
- Journal of Clinical Oncology
- Published
- 1997-11
- Volume
- 15
- Issue
- 11
- Pages
- 3363-3367
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1820106848
- Cited by
- 345
- References
- 9
- FWCI
- 4.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. https://app.cochat.ai/papers/10.1200/jco.1997.15.11.3363
- The paper
- Disis, M. L., Pupa, S. M., Gralow, J. R., Dittadi, R., Menard, S., & Cheever, M. A. (1997). High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1997.15.11.3363
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.